Hyderabad, Jul 3 (UNI): Bharat Biotech, a global leader in vaccine development and innovation, announced on Saturday safety and efficacy analysis data from Phase III clinical trials of COVAXIN®, a whole virion inactivated vaccine against SARS-CoV2, was developed in partnership with ICMR and NIV Pune.
The vaccine maker claimed that the efficacy analysis demonstrates COVAXIN® to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
It said Efficacy analysis demonstrates COVAXIN® to be 93.4% effective against severe symptomatic COVID-19 and Safety analysis demonstrates adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events
The biotechnology company said Efficacy data demonstrates 63.6% protection against asymptomatic COVID-19 and Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant.
Bharat Biotech in a statement said Phase 3 clinical trials of COVAXIN® was an event driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India.